Stay updated with breaking news from Tycel Phillips. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tycel Phillips, MD, MPH, discusses treatment options for patients with relapsed/refractory mantle cell lymphoma who have progressed on covalent BTK inhibitors.
Tycel Phillips, MD, discusses the significance of the FDA approval of the bispecific antibody epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Results from phase 2 clinical trial demonstrated EPKINLY (epcoritamab-bysp) delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median duration of response in
Company Announcement Results from phase 2 clinical trial demonstrated EPKINLY™ delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median duration of... | May 19, 2023
Tycel Phillips, MD, discusses the significance of the FDA approval of the bispecific antibody epcoritamab in patients with relapsed/refractory large B-cell lymphoma.